S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Latest freight railroad layoffs and Wall Street pressure renew concerns about safety and service
Critical asset just had biggest fall on record (Ad)
One year after buying a failed bank, New York Community Bancorp is struggling
Dell, NetApp rise; Ginkgo Bioworks, New York Community Bancorp fall, Friday, 3/1/2024
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Friday, 3/1/2024
China pledges to increase opportunities for foreign companies as it seeks to boost its economy
Critical asset just had biggest fall on record (Ad)
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Latest freight railroad layoffs and Wall Street pressure renew concerns about safety and service
Critical asset just had biggest fall on record (Ad)
One year after buying a failed bank, New York Community Bancorp is struggling
Dell, NetApp rise; Ginkgo Bioworks, New York Community Bancorp fall, Friday, 3/1/2024
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Friday, 3/1/2024
China pledges to increase opportunities for foreign companies as it seeks to boost its economy
Critical asset just had biggest fall on record (Ad)
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Latest freight railroad layoffs and Wall Street pressure renew concerns about safety and service
Critical asset just had biggest fall on record (Ad)
One year after buying a failed bank, New York Community Bancorp is struggling
Dell, NetApp rise; Ginkgo Bioworks, New York Community Bancorp fall, Friday, 3/1/2024
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Friday, 3/1/2024
China pledges to increase opportunities for foreign companies as it seeks to boost its economy
Critical asset just had biggest fall on record (Ad)
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Latest freight railroad layoffs and Wall Street pressure renew concerns about safety and service
Critical asset just had biggest fall on record (Ad)
One year after buying a failed bank, New York Community Bancorp is struggling
Dell, NetApp rise; Ginkgo Bioworks, New York Community Bancorp fall, Friday, 3/1/2024
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Friday, 3/1/2024
China pledges to increase opportunities for foreign companies as it seeks to boost its economy
Critical asset just had biggest fall on record (Ad)
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
NASDAQ:AMRX

Amneal Pharmaceuticals (AMRX) Stock Price, News & Analysis

$5.47
-0.05 (-0.91%)
(As of 03/1/2024 ET)
Today's Range
$5.01
$6.15
50-Day Range
$5.24
$6.21
52-Week Range
$1.24
$6.30
Volume
5.95 million shs
Average Volume
1.49 million shs
Market Capitalization
$1.68 billion
P/E Ratio
91.17
Dividend Yield
N/A
Price Target
$5.40

Amneal Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
1.3% Downside
$5.40 Price Target
Short Interest
Healthy
1.91% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.65mentions of Amneal Pharmaceuticals in the last 14 days
Based on 22 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
2.04%
From $0.49 to $0.50 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.80 out of 5 stars

Medical Sector

631st out of 951 stocks

Pharmaceutical Preparations Industry

295th out of 428 stocks


AMRX stock logo

About Amneal Pharmaceuticals Stock (NASDAQ:AMRX)

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson's disease, and endocrine disorders. This segment also provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid for the treatment of hypothyroidism; and IPX203, a pipeline product for Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

AMRX Stock Price History

AMRX Stock News Headlines

6 reasons to buy Teva Pharmaceuticals stock sooner than later (AMRX)
Investors seeking a long-term and undervalued pharmaceutical play should take a close look at Teva Pharmaceuticals, and here are six reasons why
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Amneal Pharmaceuticals: Q4 Earnings Insights
Amneal Pharmaceuticals Up 20% In Pre-market - Update
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Here's what to expect from Amneal Pharmaceuticals A's earnings report
Amneal to Participate at Upcoming Investor Conference
Top 3 Pharma Stocks With Bullish Momentum
Knight Therapeutics Inks License Agreement With Amneal Pharma For IPX203
See More Headlines
Receive AMRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amneal Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/05/2023
Today
3/01/2024
Next Earnings (Confirmed)
3/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:AMRX
Previous Symbol
NASDAQ:AMRX
Employees
7,600
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$5.40
High Stock Price Target
$8.00
Low Stock Price Target
$3.00
Potential Upside/Downside
-1.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

Net Income
$-129,990,000.00
Pretax Margin
1.49%

Debt

Sales & Book Value

Annual Sales
$2.21 billion
Cash Flow
$1.41 per share
Book Value
$0.61 per share

Miscellaneous

Free Float
225,126,000
Market Cap
$1.68 billion
Optionable
Optionable
Beta
1.34
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives















AMRX Stock Analysis - Frequently Asked Questions

Should I buy or sell Amneal Pharmaceuticals stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Amneal Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" AMRX shares.
View AMRX analyst ratings
or view top-rated stocks.

What is Amneal Pharmaceuticals' stock price target for 2024?

5 Wall Street research analysts have issued 12 month target prices for Amneal Pharmaceuticals' stock. Their AMRX share price targets range from $3.00 to $8.00. On average, they anticipate the company's stock price to reach $5.40 in the next twelve months. This suggests that the stock has a possible downside of 1.3%.
View analysts price targets for AMRX
or view top-rated stocks among Wall Street analysts.

How have AMRX shares performed in 2024?

Amneal Pharmaceuticals' stock was trading at $6.07 on January 1st, 2024. Since then, AMRX stock has decreased by 9.9% and is now trading at $5.47.
View the best growth stocks for 2024 here
.

Are investors shorting Amneal Pharmaceuticals?

Amneal Pharmaceuticals saw a decline in short interest in the month of February. As of February 15th, there was short interest totaling 2,100,000 shares, a decline of 17.3% from the January 31st total of 2,540,000 shares. Based on an average daily volume of 1,360,000 shares, the days-to-cover ratio is currently 1.5 days. Approximately 1.9% of the shares of the company are sold short.
View Amneal Pharmaceuticals' Short Interest
.

How were Amneal Pharmaceuticals' earnings last quarter?

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) posted its earnings results on Friday, May, 5th. The company reported $0.10 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.09 by $0.01. The company had revenue of $557.54 million for the quarter, compared to analyst estimates of $555 million. Amneal Pharmaceuticals had a trailing twelve-month return on equity of 109.82% and a net margin of 0.43%. During the same period in the prior year, the firm earned $0.10 EPS.

What guidance has Amneal Pharmaceuticals issued on next quarter's earnings?

Amneal Pharmaceuticals updated its FY 2024 earnings guidance on Friday, March, 1st. The company provided earnings per share (EPS) guidance of 0.530-0.630 for the period, compared to the consensus estimate of 0.600. The company issued revenue guidance of $2.6 billion-$2.7 billion, compared to the consensus revenue estimate of $2.6 billion.

Who are Amneal Pharmaceuticals' major shareholders?

Amneal Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (4.45%), Rubric Capital Management LP (2.61%), Dimensional Fund Advisors LP (0.92%), Nantahala Capital Management LLC (0.76%), Nuveen Asset Management LLC (0.64%) and Charles Schwab Investment Management Inc. (0.43%). Insiders that own company stock include Andrew S Boyer, Chirag K Patel, Gautam Patel, Joseph Todisco, Nikita Shah and Tpg Gp A, Llc.
View institutional ownership trends
.

How do I buy shares of Amneal Pharmaceuticals?

Shares of AMRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AMRX) was last updated on 3/2/2024 by MarketBeat.com Staff